Literature DB >> 14576519

Anti-ischemic effects of ivabradine, a selective heart rate-reducing agent, in exercise-induced myocardial ischemia in pigs.

Jean-Paul Vilaine1, Jean-Pierre Bidouard, Ludovic Lesage, Hélène Reure, Jean-Louis Péglion.   

Abstract

The effects of ivabradine, a novel heart rate-reducing agent that inhibits the cardiac pacemaker current If, were compared with those of the beta-adrenergic blocker propranolol, in a model of exercise-induced regional myocardial ischemia in pigs. Five Yucatan micropigs were chronically instrumented to measure hemodynamics, regional myocardial contractility, and local electrograms, and a fixed stenosis of the left anterior descending coronary artery was induced using a clip. Each animal underwent three experiments on different days, each consisting of two treadmill exercise sessions, 4 hours apart. Ivabradine 5 mg/kg, propranolol 5 mg/kg, or vehicle was administered orally 3 hours before the second exercise session. Exercises before treatment and after vehicle produced reproducible hemodynamic changes and regional myocardial ischemia in the area perfused by the stenosed coronary artery, indicated by ST segment shift and regional contractile dysfunction. Ivabradine and propranolol were equipotent in reducing heart rate at rest and limiting tachycardia during exercise. Ivabradine, unlike propranolol, did not reduce left ventricular contractility at rest or during exercise, and did not increase atrio-ventricular conduction time. Both compounds reduced the exercise-induced ST segment shift in the ischemic region by approximately 80%, but ivabradine preserved systolic shortening to a significantly greater degree than propranolol (P < 0.05).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14576519     DOI: 10.1097/00005344-200311000-00016

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  16 in total

Review 1.  Heart rate: a forgotten link in coronary artery disease?

Authors:  Kim M Fox; Roberto Ferrari
Journal:  Nat Rev Cardiol       Date:  2011-04-26       Impact factor: 32.419

2.  Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise.

Authors:  Robinson Joannides; Nicholas Moore; Michaela Iacob; Patricia Compagnon; Guy Lerebours; Jean-François Menard; Christian Thuillez
Journal:  Br J Clin Pharmacol       Date:  2006-02       Impact factor: 4.335

3.  Heart rate reduction by inhibition of If or by beta-blockade has different effects on postsystolic wall thickening.

Authors:  L Lucats; B Ghaleh; P Colin; X Monnet; A Bizé; A Berdeaux
Journal:  Br J Pharmacol       Date:  2006-12-18       Impact factor: 8.739

4.  Pleiotropic, heart rate-independent cardioprotection by ivabradine.

Authors:  P Kleinbongard; N Gedik; P Witting; B Freedman; N Klöcker; G Heusch
Journal:  Br J Pharmacol       Date:  2015-07-21       Impact factor: 8.739

Review 5.  Ivabradine in Patients with Stable Coronary Artery Disease: A Rationale for Use in Addition to and Beyond Percutaneous Coronary Intervention.

Authors:  Cosmo Godino; Antonio Colombo; Alberto Margonato
Journal:  Clin Drug Investig       Date:  2017-02       Impact factor: 2.859

Review 6.  Preclinical results with I(f) current inhibition by ivabradine.

Authors:  Alain Berdeaux
Journal:  Drugs       Date:  2007       Impact factor: 9.546

7.  Niflumic acid alters gating of HCN2 pacemaker channels by interaction with the outer region of S4 voltage sensing domains.

Authors:  Lan Cheng; Michael C Sanguinetti
Journal:  Mol Pharmacol       Date:  2009-02-13       Impact factor: 4.436

8.  The effects of ivabradine on left atrial electromechanical function in patients with systolic heart failure.

Authors:  Serkan Ozturk; Selçuk Öztürk; Fatma Hizal Erdem; Alim Erdem; Selim Ayhan; İbrahim Dönmez; Mehmet Yazıcı
Journal:  J Interv Card Electrophysiol       Date:  2016-04-02       Impact factor: 1.900

Review 9.  Heart rate in the pathophysiology of coronary blood flow and myocardial ischaemia: benefit from selective bradycardic agents.

Authors:  G Heusch
Journal:  Br J Pharmacol       Date:  2008-01-28       Impact factor: 8.739

Review 10.  Heart rate lowering by specific and selective I(f) current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease.

Authors:  Dario DiFrancesco; John A Camm
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.